An official website of the United States government
Home
Name
Vendexta
Alternate Names
Venetoclax
Abbreviations
None
Category
Chemotherapy
Subcategory
BCL2 Inhibitor
NSC Number
None
Primary Site
None
Histology
Lymphoma
Remarks
6/15/2018: FDA has approved, under priority review, Venclexta (venetoclax tablets) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, with or without 17p deletion, who have received at least one prior therapy
Coding
This drug should be coded
